Eczema ‐ Infancy (incidence) · infants
It is very uncertain whether prolonged feeding: hydrolysed formula changes eczema ‐ Infancy (incidence) compared with cow's milk formula (very low certainty).
1 finding from 1 review
Rhinitis ‐ Infancy (incidence) · infants
It is very uncertain whether prolonged feeding: hydrolysed formula changes rhinitis ‐ Infancy (incidence) compared with cow's milk formula (very low certainty).
1 finding from 1 review
Food allergy ‐ Infancy (incidence) · infants
It is very uncertain whether prolonged feeding: hydrolysed formula changes food allergy ‐ Infancy (incidence) compared with cow's milk formula (very low certainty).
1 finding from 1 review
Cow's milk allergy ‐ infancy (incidence) · infants
It is very uncertain whether prolonged feeding: hydrolysed formula changes cow's milk allergy ‐ Infancy (incidence) compared with cow's milk formula (very low certainty).
1 finding from 1 review
Catheter‐related blood stream infection · patients with a central venous catheter
Longer intervals (5‐15 days) (intervention) showed no clear difference in catheter‐related blood stream infection (CRBSI) compared with shorter intervals (2‐5 days) (control) between dressing changes (low certainty).
1 finding from 1 review
RR 1.42 [0.4, 4.98]
Studies not reported
Low
All‐cause mortality · patients with a central venous catheter
Longer intervals (5‐15 days) (intervention) showed no clear difference in all‐cause mortality compared with shorter intervals (2‐5 days) (control) between dressing changes (low certainty).
1 finding from 1 review
RR 1.06 [0.9, 1.25]
Studies not reported
Low
Skin damage № of participants: 1587 (4 RCTs) · patients with a central venous catheter
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Pain № of participants: 193 (2 RCTs) · patients with a central venous catheter
Longer intervals (5‐15 days) (intervention) showed no clear difference in pain № of participants: 193 (2 RCTs) compared with shorter intervals (2‐5 days) (control) between dressing changes (low certainty).
1 finding from 1 review
RR 0.8 [0.46, 1.38]
Studies not reported
Low
Number of ulcer-free days and number of new ulcers · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review
Forty patients were randomised to receive LongoVital (herbal plus vitamin) or placebo (Kolseth 2005). Data presented as medians with 95% confidence intervals, unsuitable for further analysis. The authors report no…
1 study · 40 participants
GRADE not reported
Adverse effects · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review
Quality of life · women with heavy menstrual bleeding
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: headache · women with heavy menstrual bleeding
Progestogen therapy long cycle (3 to 4 weeks) showed no clear difference in adverse effect Headache compared with other medical therapy (low certainty).
1 finding from 1 review
Adverse effect Breakthrough bleeding/spotting · women with heavy menstrual bleeding
Progestogen therapy long cycle (3 to 4 weeks) may leads to lower adverse effect Breakthrough bleeding/spotting compared with other medical therapy (low certainty).
1 finding from 1 review
Menstrual blood loss PBAC score · women with heavy menstrual bleeding
2 findings from 1 review
Satisfaction · women with heavy menstrual bleeding
Progestogen therapy long cycle (3 to 4 weeks) may leads to lower satisfaction compared with other medical therapy (low certainty).
1 finding from 1 review
Days of bleeding · women with heavy menstrual bleeding
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Antibody response (geometric mean titre) · 9‐ to 14‐year‐old females and males
1 finding from 1 review
Invasive cervical, vaginal, vulval, anal, or penile cancer · 9‐ to 14‐year‐old females and males
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
High‐grade cervical, vulval, vaginal, penile, or anal intraepithelial neoplasia · 9‐ to 14‐year‐old females and males
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall local/injection site adverse events · 9‐ to 14‐year‐old females and males
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found